Select Page
EPHA #A2M Dialogues

A series of online, live, public dialogues putting the spotlight on actionable solutions on access to medicines for decision-makers in Europe. 

EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

#A2M Dialogues

Register for our upcoming events below

Unleashing meaningful innovation through regulatory reform

19 October | 17:00-18:00

What effect do the shortcomings of current assessment processes have on the quality of innovation?

How do we resolve the conundrum of high prices and high uncertainty?

Join us to discuss concrete recommendations on how regulatory and payment systems can be adapted to benefit patients, clinicians and healthcare systems

The EU's IP strategy: Enabler or barrier?

27 October | 17:00-18:00

How do we ensure that IP incentives compensate and reward innovation but do not distort competition?

What lessons have we learned on IP in the response to COVID19?

Our experts and key stakeholders will discuss what change is necessary to serve the needs of all patients while guaranteeing healthy prices and competition

Pharma & COVID19: Winners, losers, prospects

19 November | 16:00-17:00

Is the affordability debate in Europe changing in the light of COVID19?

Who are the big winners and losers?

Join a venture capitalist investing in pharma, a leading access to medicines advocate and an expert in the science and economics of drug R&D us to discuss how COVID19 has reshaped the dynamics within the sector, as well as between industry and European governments. 

The Presidencies' perspective on the pharmaceutical strategy: Europe's to-do list on access to medicines

25 November | 16:00-17:30

The EU’s Pharmaceutical Strategy is due to be published on 24 November  by the European Commission. 

Senior representatives of the German, Portuguese and Slovenian Presidencies will offer their perspective on what should be prioritised and debate the next steps in European pharmaceutical policy

Follow on social media




Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines, EPHA